Management confirmed the acceleration of the CBeyond trial timeline with topline data expected ... and manufacturing costs for nimacimab trials. General and administrative expenses rose to $4 ...

CERo's forward-looking statements emphasize the uncertainties and risks involved in their business strategy and clinical trial timelines ... is among the final steps necessary to have completed ...